p16INK4a Expression and Clinicopathologic Parameters in Renal Cell Carcinoma

European Urology

Volumn 51, Issue 3, 2007, Pages 732-738

  Ikuerowo, Stephen O ^a   Kuczyk, Markus A ^b   von Wasielewski, Reinhard ^a   Shittu, Olayiwola B ^c   Jonas, Udo ^a   Machtens, Stefan ^a   Serth, Jürgen ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF IBADAN   (Nigeria)

Author keywords

p16INK4a; Prognosis; Renal cell cancer; Tissue microarray analysis

Indexed keywords

PROTEIN P16INK4A;

ADULT; AGED; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; COVARIANCE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEPHRECTOMY; P16INK4A GENE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REGRESSION ANALYSIS; TISSUE MICROARRAY; TUMOR CELL; TUMOR SUPPRESSOR GENE;

CARCINOMA, RENAL CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE;

EID: 33846224772     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2006.08.010     Document Type: Article

References (34)

1. Landis S.H., Murray T., Bolden S., and Wingo P.A. Cancer statistics, 1999. CA Cancer J Clin 49 (1999) 8-31
2. Motzer R.J., Russo P., Nanus D.M., and Berg W.J. Renal cell carcinoma. Curr Probl Cancer 21 (1997) 185-232
3. Patel P.H., Chaganti R.S., and Motzer R.J. Targeted therapy for metastatic renal cell carcinoma. Br J Cancer 94 (2006) 614-619
4. Negrier S., Escudier B., Gomez F., et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie. Ann Oncol 13 (2002) 1460-1468
5. Kattan M.W., Reuter V., Motzer R.J., Katz J., and Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J Urol 166 (2001) 63-67
6. Sorbellini M., Kattan M.W., Snyder M.E., et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 173 (2005) 48-51
7. Ficarra V., Novara G., Galfano A., and Artibani W. Neoplasm staging and organ-confined renal cell carcinoma: a systematic review. Eur Urol 46 (2004) 559-564
8. Sherr C.J. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 60 (2000) 3689-3695
9. Sherr C.J. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2 (2001) 731-737
10. Beasley M.B., Lantuejoul S., Abbondanzo S., et al. The P16/cyclin D1/Rb pathway in neuroendocrine tumors of the lung. Hum Pathol 34 (2003) 136-142
11. Hedberg Y., Ljungberg B., Roos G., and Landberg G. Expression of cyclin D1, D3, E, and p27 in human renal cell carcinoma analysed by tissue microarray. Br J Cancer 88 (2003) 1417-1423
12. Sanz-Casla M.T., Maestro M.L., del Barco V., et al. Loss of heterozygosity and methylation of p16 in renal cell carcinoma. Urol Res 31 (2003) 159-162
13. Mengel M., Kreipe H., and von Wasielewski R. Rapid and large-scale transition of new tumor biomarkers to clinical biopsy material by innovative tissue microarray systems. Appl Immunohistochem Mol Morphol 11 (2003) 261-268
14. Guinan P., Sobin L.H., Algaba F., et al. TNM staging of renal cell carcinoma: Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80 (1997) 992-993
15. Fuhrman S.A., Lasky L.C., and Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6 (1982) 655-663
16. Kovacs G., Akhtar M., Beckwith B.J., et al. The Heidelberg classification of renal cell tumours. J Pathol 183 (1997) 131-133
17. Ikuerowo S.O., Kuczyk M.A., Mengel M., et al. Alteration of subcellular and cellular expression patterns of cyclin B1 in renal cell carcinoma is significantly related to clinical progression and survival of patients. Int J Cancer 119 (2006) 867-874
18. Liggett Jr. W.H., and Sidransky D. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 16 (1998) 1197-1206
19. Kawada Y., Nakamura M., Ishida E., et al. Aberrations of the p14(ARF) and p16(INK4a) genes in renal cell carcinomas. Jpn J Cancer Res 92 (2001) 1293-1299
20. Kamb A., Gruis N.A., Weaver-Feldhaus J., et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 264 (1994) 436-440
21. Hedberg Y., Ljungberg B., Roos G., and Landberg G. Retinoblastoma protein in human renal cell carcinoma in relation to alterations in G1/S regulatory proteins. Int J Cancer 109 (2004) 189-193
22. Cui X., Shirai Y., Wakai T., Yokoyama N., Hirano S., and Hatakeyama K. Aberrant expression of pRb and p16(INK4), alone or in combination, indicates poor outcome after resection in patients with colorectal carcinoma. Hum Pathol 35 (2004) 1189-1195
23. Svensson S., Nilsson K., Ringberg A., and Landberg G. Invade or proliferate? Two contrasting events in malignant behavior governed by p16(INK4a) and an intact Rb pathway illustrated by a model system of basal cell carcinoma. Cancer Res 63 (2003) 1737-1742
24. Weinberger P.M., Yu Z., Haffty B.G., et al. Prognostic significance of p16 protein levels in oropharyngeal squamous cell cancer. Clin Cancer Res 10 (2004) 5684-5691
25. Klussmann J.P., Gultekin E., Weissenborn S.J., et al. Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol 162 (2003) 747-753
26. Zhao P., Hu Y.C., and Talbot I.C. Expressing patterns of p16 and CDK4 correlated to prognosis in colorectal carcinoma. World J Gastroenterol 9 (2003) 2202-2206
27. Lee C.T., Capodieci P., Osman I., et al. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer. Clin Cancer Res 5 (1999) 977-983
28. Henshall S.M., Quinn D.I., Lee C.S., et al. Overexpression of the cell cycle inhibitor p16INK4A in high-grade prostatic intraepithelial neoplasia predicts early relapse in prostate cancer patients. Clin Cancer Res 7 (2001) 544-550
29. Omura-Minamisawa M., Diccianni M.B., Chang R.C., et al. p16/p14(ARF) cell cycle regulatory pathways in primary neuroblastoma: p16 expression is associated with advanced stage disease. Clin Cancer Res 7 (2001) 3481-3490
30. Yuen P.W., Man M., Lam K.Y., and Kwong Y.L. Clinicopathological significance of p16 gene expression in the surgical treatment of head and neck squamous cell carcinomas. J Clin Pathol 55 (2002) 58-60
31. Geisler S.A., Olshan A.F., Weissler M.C., et al. p16 and p53 Protein expression as prognostic indicators of survival and disease recurrence from head and neck cancer. Clin Cancer Res 8 (2002) 3445-3453
32. Wang L., Qi X., Sun Y., Liang L., and Ju D. Adenovirus-mediated combined P16 gene and GM-CSF gene therapy for the treatment of established tumor and induction of antitumor immunity. Cancer Gene Ther 9 (2002) 819-824
33. Stadler W.M., Vogelzang N.J., Amato R., et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. J Clin Oncol 18 (2000) 371-375
34. Aklilu M., Kindler H.L., Donehower R.C., Mani S., and Vokes E.E. Phase II study of flavopiridol in patients with advanced colorectal cancer. Ann Oncol 14 (2003) 1270-1273